Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neuroscience -- Ignore unavailable to you. Want to Upgrade?

To: Nikole Wollerstein who wrote (111)	10/21/2000 8:12:58 PM
From: Marty	Read Replies (1) \| Respond to of 278

Well, while "buy of a lifetime" was too enthusiastic that early in the game, the story isn't over yet. You could have bought the stock much cheaper since then but that has not been because the drug has disappointed or there is any less promise for it. They are still 3 to 4 years ahead of anyone else in the field. In fact, there was a study just released that indicated that Neotrofin reduced amyloid plaques and they are the only company with a drug with those properties actually in human trials. That wasn't even suspected in Aug 1999. Fortunately, the drug has been proving out and it appears that they are still learning more about it in the trial process. So far, so good. biz.yahoo.com I am not qualified to comment on how simple a compound it is or how specific it is but you may find out more on this on their web site at neotherapeutics.com. I hope you will share your reactions as I am curious as to why, with such potential and this far along in trials, it isn't more generally known. Perhaps there are a lot of other prospects around that are just as promising.

To: Nikole Wollerstein who wrote (111)	10/22/2000 11:03:08 PM
From: Marty	Respond to of 278

Talk about "moving along"! What does this list of job openings at NEOT look like to you Masters of Neuroscience on this board? neotherapeutics.com The link comes from a super sleuth on the Yahoo thread. It looks to me like NEOT is looking to beef up the organization with some heavy hitters to handle what they must believe they have.

To: Nikole Wollerstein who wrote (111)	10/23/2000 8:19:22 AM
From: scott_jiminez	Read Replies (1) \| Respond to of 278

Nikita - Perhaps you could help me more fully understand the mechanism of section of AIT-082 (leteprinim; here's a summary abstract ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10845757&dopt=Abstract). AIT-082 is a purine derivative* that appears to enhance growth factor production in the CNS...while having the significant benefit of crossing the BBB by a non-saturable influx mechanism. AIT-082 has also been around since (at least) 1994 so I'm curious why there hasn't been more interest in it (unless NEOT has strict exclusivity). Also, surely other related purine derivatives, especially guanosine- and GTP-related, would have similar effects on astrocyte derived FGF, NGF, NT-3, etc. production There's also my long standing concern that the presence of significantly elevated levels of GFs in the CNS may lead to ectopic axonal sprouting unrelated to and/or far in excess of that required for amelioration of the pathology-derived damage. In short, do the benefits really outweigh the risks? I guess my other question/concern is this - is a 'simple' yet ubiquitous (the parent purine is certainly common) compound really 'specific' for astrocyte-derived GF production or are there other, more subtle, effects that will only surface with more extended use? The fact that there are only 8 papers found by PubMed for 'AIT-082' suggests that AD, PD, etc. remain as stubbornly elusive to straightforward approaches as ever. *AIT-082 = 4-[[3-(1,6-dihydro-6-oxo-9-purin-9-yl)-1- oxopropyl]amino]benzoic acid